Thursday, 2 December 2021

Australia's most trusted
source of pharma news

Thursday, 02 December 2021

AZ, Pfizer in Delta photo finish

Posted 26 October 2021 PM

In a neck-and-neck finish, both Pfizer's Comirnaty and AstraZeneca's Vaxzevria have emerged as at least 90 per cent effective in preventing deaths from the Delta COVID-19 variant, according to a new study from Scotland.

Results recently published as a letter in The New England Journal of Medicine, reveal overall vaccine effectiveness in double vaccinated people who had tested positive for COVID-19 is 90 per cent for Comirnaty and 91 per cent for Vaxzevria.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.